SLAMF6 and neoplasm: Co-administering anti-SLAMF6/CD352 monoclonal antibody with the Bruton tyrosine kinase inhibitor, ibrutinib, synergized to efficiently eliminate the tumor cells in the spleen, bone marrow, liver, and the peritoneal cavity.